Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Chronic Hepatitis C Drug – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Chronic Hepatitis C Drug market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hepatologists, infectious disease physicians, and public health programs, chronic hepatitis C virus (HCV) infection affects approximately 58 million people globally, leading to cirrhosis, hepatocellular carcinoma (HCC), and liver failure. Prior to 2014, treatment involved pegylated interferon (injectable, 48 weeks) with low cure rates (40-50%) and severe side effects. Direct-acting antivirals (DAAs) – oral drugs targeting HCV NS3/4A, NS5A, and NS5B – revolutionized treatment, achieving >95% sustained virologic response (SVR) (cure) with 8-12 week, all-oral, well-tolerated regimens. Pangenotypic DAAs (effective across all HCV genotypes 1-6) simplified therapy, eliminating need for genotyping. The chronic hepatitis C drug market has transformed from a high-priced specialty market to a generic-driven, curative, high-volume public health market, aiming for WHO 2030 elimination. The global market for Chronic Hepatitis C Drug was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975084/chronic-hepatitis-c-drug
Understanding Chronic Hepatitis C Therapies: DAA Curative Regimens
Direct-acting antivirals revolutionized HCV treatment (2014 onward). Key drug classes:
- NS3/4A protease inhibitors: Glecaprevir, grazoprevir, voxilaprevir.
- NS5A inhibitors: Ledipasvir, velpatasvir, pibrentasvir, elbasvir.
- NS5B polymerase inhibitors (nucleotide): Sofosbuvir (prodrug, chain terminator).
Current first-line pangenotypic oral regimens (WHO, AASLD, EASL guidelines):
- Sofosbuvir/velpatasvir (Epclusa® – Gilead): 12 weeks, pangenotypic (genotypes 1-6). Also 24 weeks for decompensated cirrhosis.
- Glecaprevir/pibrentasvir (Mavyret® / Maviret® – AbbVie): 8 weeks for non-cirrhotic, treatment-naïve patients (shortest duration). Pangenotypic.
- Sofosbuvir/velpatasvir/voxilaprevir (Vosevi® – Gilead): Retreatment after DAA failure.
Genotype-specific regimens (declining): ledipasvir/sofosbuvir (Harvoni® – genotypes 1,4,5,6), elbasvir/grazoprevir (Zepatier® – genotypes 1,4), daclatasvir + sofosbuvir.
Injectable drugs (older, obsolete): Pegylated interferon + ribavirin (Peg-IFN/RBV). Low cure rates, severe side effects. No longer recommended (except resource-limited settings without DAA access). Injectable share negligible (<1% in high-income countries, decreasing in LMICs).
Key endpoints: Sustained virologic response (SVR) – undetectable HCV RNA 12 weeks after treatment completion (cure). SVR rates >95% for DAA regimens. Prevents cirrhosis, HCC, transmission.
WHO elimination goals (2030): 90% diagnosed, 80% treated (of eligible). Currently 10-20% diagnosed, 5-10% treated globally. Massive scale-up needed.
Market Segmentation by Drug Type
- Oral Drugs (Dominant, ~99% of market value): DAAs – fixed-dose combination tablets (Epclusa, Mavyret, Harvoni), once daily. High efficacy, minimal side effects. Oral segment comprises:
- Branded DAAs (Gilead, AbbVie, Merck): High price ($20,000-90,000 per course in US, EU; lower in LMICs via licensing).
- Generic DAAs (Mylan, Cipla, Natco, Hetero, Dr. Reddy’s, generic manufacturers): Low price ($150-2,000 per course). WHO prequalified. Essential for public health programs.
Market shift from branded to generic (post-patent expiry, voluntary licensing). In high-income countries, branded still used (insurance coverage, physician preference). Generic share growing globally.
- Injectable Drugs (Negligible, <1%): Pegylated interferon + ribavirin (branded Pegasys®, PegIntron®). Subcutaneous injection, 48 weeks. Low efficacy, poor tolerability. Discontinued in most countries. Only in resource-limited settings where DAAs inaccessible (due to cost, regulatory barriers). Share declining to zero.
Market Segmentation by Application (End-User)
- Hospital (Largest, ~60-65% of market value): HCV treatment historically managed by hepatologists, gastroenterologists in hospital clinics. DAA prescribing (specialty medications, prior authorization). Monitoring (viral load, liver function). Cirrhotic patients, decompensated liver disease, liver transplant recipients, HIV-HCV co-infection require hospital-based care. Hospital pharmacy distributes expensive branded DAAs, specialty distribution. Hospital share declining (shift to community).
- Clinic (Fastest-Growing, ~25-30%): Primary care clinics, federally qualified health centers, addiction treatment centers, harm reduction programs, community health centers increasingly prescribing DAAs for uncomplicated HCV (non-cirrhotic, treatment-naïve). Task-shifting from specialists to nurse practitioners, primary care physicians. Telemedicine HCV treatment (self-administered oral DAAs, remote monitoring). Clinic segment growth (10-15% annually) driven by generic availability, simplified pangenotypic regimens.
- Others (Prisons, substance use treatment, pharmacies, mobile health units) (~10%): High prevalence populations (incarcerated persons, people who inject drugs – PWID). DAA treatment reduces transmission. Pharmacist-led treatment (UK, Canada). Mobile clinics. Expanding.
Competitive Landscape and Exclusive Market Observation (2025–2026)
Key Players: Gilead Sciences (market leader, revolutionized HCV with sofosbuvir – Sovaldi® 2013, Harvoni® 2014, Epclusa® 2016, Vosevi® 2017. Extensive patent portfolio, voluntary licensing via Medicines Patent Pool to generic manufacturers for 112+ low/middle-income countries. Branded DAA sales peaked 2015 at 19.1B,declinedto19.1B,declinedto2-3B 2025. Epclusa patent expires 2028 (US), Vosevi 2029. Generics eroding market), Bristol Myers Squibb (daclatasvir – Daklinza®, genotype 1-4, exited HCV market? generic available; BMS no longer active in HCV), AbbVie (Mavyret® – glecaprevir/pibrentasvir, pangenotypic 8 weeks, strong market share in North America, Europe, Japan. Patent expiry later (2030+). AbbVie also licensed to generic manufacturers for LMICs), Johnson & Johnson (no current DAA), Boehringer Ingelheim (no DAA), Merck (Zepatier® – elbasvir/grazoprevir, genotype 1,4; share minimal), Kawin Technology (Chinese biotech, generic DAAs for domestic market – sofosbuvir, daclatasvir, velpatasvir. Competing in China VBP).
Exclusive Industry Insight (H1 2026): Chronic hepatitis C drug market is post-peak, generic-driven, with high-volume public health focus:
- Peak market (2015-2016): Sovaldi 84,000/12−weekcourse,Harvoni84,000/12−weekcourse,Harvoni94,500, Mavyret 79,800.Globalsales>79,800.Globalsales>20 billion. Unaffordable for many countries.
- Current landscape (2025-2026):
- Generic DAAs available (India, Egypt, China, Brazil, Bangladesh, Pakistan) at $150-500 per 12-week course. WHO prequalified generics (Mylan, Cipla, Natco, Hetero, Dr. Reddy’s, Zydus, Strides, Emcure, Apotex). Global Fund, Unitaid, Clinton Health Access Initiative (CHAI) negotiate low prices. National HCV elimination programs (Egypt, Pakistan, India, China, Georgia, Rwanda, Brazil) procuring generics.
- High-income countries (US, EU, Japan, Canada, Australia) originator prices remain high ($20,000-40,000 per course) but discounted via insurance, rebates, government price controls. Generic entry delayed by patents. Patient numbers treated (in US: ~100,000 annually down from peak 200,000).
- WHO elimination progress: Egypt (largest HCV prevalence >10% adults) treated >4 million patients through national screening, claimed elimination (2023? WHO validation pending). Pakistan (8-10% prevalence) treated >3 million (World Bank, Global Fund). China, India, Brazil scaling up.
- Market value vs. volume: Revenue declining (CAGR -5% to -10%) due to price erosion. Volume increasing (CAGR +5% to +8%) due to treated patient expansion. Sustainable low price equilibrium.
User case: India (2025) – National Hepatitis Control Program procures generic sofosbuvir/velpatasvir (Epclusa generic) at $150-200 per 12-week course (Mylan, Cipla, Natco, Hetero, others). Treated >2 million patients (since 2018). Elimination target 2030. Community health workers, primary care clinics prescribe (task-shifting). Dried blood spot testing (GeneXpert, point-of-care). High cure rates (>95%), reduces transmission.
User case 2: Egypt (2025) – National HCV elimination program (100 Million Healthy Lives campaign, 2018-2020) screened 50 million adults, treated >4 million with generic DAAs (sofosbuvir + daclatasvir, later Epclusa generic). Reduced prevalence from 10% to <2% (modeled). Documented decline in HCV-related mortality, HCC incidence. WHO elimination status pending (gold tier). Template for other countries.
Technical Deep Dive: Pangenotypic Oral DAA Advantages
Pangenotypic DAAs (Epclusa, Mavyret) effective against HCV genotypes 1-6 (subtypes 1a, 1b, 2a, 2b, 3a, 4,5,6). Advantages:
- No genotyping required – saves cost, simplifies treatment, reduces delays. Important in resource-limited settings.
- High barrier to resistance – requires multiple mutations before clinical resistance. SVR >99% in clinical trials.
- Short duration – 8 weeks (Mavyret non-cirrhotic) vs. 12 weeks (Epclusa). Improved adherence, reduced cost.
- Pregnancy safety – limited data; DAAs not recommended during pregnancy (defer until postpartum unless high risk). PEG/ribavirin contraindicated (teratogenic).
Resistance: DAA failure (non-SVR) occurs <5%. Resistance-associated substitutions (RAS) testing for retreatment (Vosevi recommended).
Future Outlook (2026–2032): Drivers, Generic Expansion, and Elimination
Growth Drivers:
- WHO elimination targets (2030): 58 million infected, 80% diagnosed, 80% treated. Current coverage <20%. Significant volume growth required. Funding gaps.
- Generic price declines: <$100 per course predicted by 2028 for low-income countries. 8-week regimen Mavyret generic also affordable.
- Simplified care models: Dried blood spot testing, telemedicine, pharmacy-based treatment. Nurse/pharmacist prescribing. Task-shifting.
- Screening expansion: One-time universal screening for adults (US CDC, USPSTF recommended; many countries). Increased diagnosis.
Constraints:
- Reinfection: PWID reinfection rate 5-15% annually (needle sharing). Requires re-treatment, harm reduction.
- Loss to follow-up: Diagnosed but not linked to care (stigma, substance use, incarceration, homelessness). Patient navigation crucial.
- High burden countries: Nigeria, Pakistan, India, China, Indonesia, Russia – millions infected, health system capacity insufficient. External funding needed.
Emerging technologies: Point-of-care HCV RNA (GeneXpert, Abbott ID NOW, Cepheid) – same-day diagnosis, treat. Integrated vaccine (prevention) – not yet available.
The market projected revenue flat/declining, volume increasing. Pangenotypic >95% share. Generic manufacturers dominate LMIC volume; originators (Gilead, AbbVie) retain high-income branded share. Asia-Pacific, Africa fastest-growing.
Contact Us
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
